Tumor buster - where will the CAR-T cell therapy 'missile' go?

Mol Cancer · 2022 · PMC9580202 · PMID 36261831

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In a multicenter, single-arm, phase 2 study (ZUMA-12, NCT03761056 ), axicabtagene ciloleucel yielded highly significant treatment outcomes in 37 patients with high-risk DLBCL, with patients achieving a complete remission (CR) rate (CRR) of 78% and an objective response (OR) rate (ORR) of 89%.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.